

East African Medical Journal Vol. 77 No. 4 April 2000

HUMAN IgG SUB-CLASS ANTIBODIES TO THE 19 KILODALTON CARBOXY TERMINAL FRAGMENT OF *PLASMODIUM FALCIPARUM* MEROZOITE SURFACE PROTEIN 1 (MSP1₁₉) AND PREDOMINANCE OF THE MAD20 ALLELIC TYPE OF MSP1 IN UGANDA.

B. Apio, BSc, Biochemistry and Chemistry, Research Associate, A. Nalunkuma, BSc, Biochemistry and Chemistry, Research Associate, Med Biotech Laboratories, Kampala, Uganda, D. Okello, MBChB, MMed, MSc, Senior Lecturer, Makerere University Medical School, Kampala, Uganda, E. Riley, BVM, MSc, PhD, Professor of Infectious Disease Immunology, London School of Hygiene and Tropical Medicine, London, UK and T. G. Egwang, BVM, MSc, PhD, Director General, Med Biotech Laboratories, Kampala, Uganda.

Request for reprints to: Dr. T. G. Egwang, Med Biotech Laboratories, Division of Medical Parasitology and Tropical Medicine, P. O. Box 9364, Kampala, Uganda.

HUMAN IgG SUBCLASS ANTIBODIES TO THE 19 KILODALTON CARBOXY TERMINAL FRAGMENT OF *PLASMODIUM FALCIPARUM* MEROZOITE SURFACE PROTEIN 1 (MSP1₁₉) AND PREDOMINANCE OF THE MAD20 ALLELIC TYPE OF MSP1 IN UGANDA

B. APIO, A. NALUNKUMA, D. OKELLO, E. RILEY and T. G. EGWANG

ABSTRACT

Objective: To determine the natural human humoral immune responses to the 19 kilodalton carboxy terminal fragment of *Plasmodium falciparum* merozoite surface protein 1 (MSP1₁₉), a malaria candidate vaccine antigen and to determine the prevalence of MAD20 and K1 alleles of *P. falciparum* MSP1.

Design: Community based cross-sectional study.

Setting: Atopi Parish, Apac District, Uganda, 1995.

Subjects: Three hundred and seventy four Ugandans between <1 and 70 years old provided serum samples.

Main outcome measures: IgG subclass antibodies by ELISA; MAD20 and K1 allelic types of MSP1 by PCR.

Results: Both the prevalence and the mean concentration of serum IgG1, and to a lesser extent IgG3, antibodies increased with age. IgG2 or IgG4 antibodies were virtually non-existent. The cross-reactivity between the 4 sequence variants (E-KNG, E-TSR, Q-KNG and Q-TSR) of MSP1₁₉ was confirmed; however, a minority of sera preferentially recognised the KNG but not the TSR variants. All 33 *P. falciparum* isolates from different parts of Uganda carried the E-TSR (Mad20) allelic type and 3 isolates were mixed infections with E-TSR (MAD20) and Q-KNG (K1) allelic types, confirming the rarity of the K1 allele in Uganda.

Conclusion: There is a robust IgG1 antibody response to the malaria vaccine candidate antigen MSP1₁₉ which begins at an early age. Future cohort studies are necessary to establish the impact of these antibodies on clinical immunity to malaria. The MAD20 allelic type of MSP1 is predominant in Ugandan *P. falciparum* isolates.

INTRODUCTION

The merozoite surface protein (MSP1), a 195 kilodalton (kD) protein on the surface of merozoites which is processed into many shorter polypeptides prior to the invasion of the erythrocyte, is the subject of intense investigations aimed at developing *Plasmodium falciparum* blood-stage vaccines(1). Evidence from in vitro and challenge studies in mice and primates suggests that a vaccine based on MSP1 might have an immunoprophylactic effect against malaria(2-5). Immunisation with recombinant *Plasmodium yoelii* MSP1(6) or a DNA vaccine encoding *Plasmodium yoelii* MSP1(7) has protected mice against *P. yoelii* sporozoite challenge; immunised mice exhibited boosting of antibody responses after infection(8). MSP1 is composed of conserved, polymorphic and dimorphic sequences. Although the carboxy terminal 42 kD fragment is dimorphic, with the two alleles being classified as MAD20-like or K1-like(9), the 19 kD fragment is essentially conserved with only 4

amino acid differences between the two dimorphic types(10). This divergence has resulted in the existence of four possible sequence variants of MSP1₁₉ which have been successfully expressed in the yeast *Saccharomyces cerevisiae* as secreted polypeptides(11).

Antibodies to the carboxy terminus of MSP1 are believed to be responsible for much of the protective effect of antibodies to native MSP1. Immunisation of rabbits with the carboxy terminal 42 kD portion of *P. falciparum* MSP1 induced antibodies, which inhibited parasite growth in vitro(12). Studies of West African children have demonstrated that the prevalence of antibodies to the C terminus of MSP1 was associated with resistance to clinical malaria and high parasitemia in young children(13,14). However, the correlation between responses to MSP1₁₉ and clinical immunity observed in West African children still remains to be confirmed in other field sites in Africa which have different malaria transmission patterns. To this end, we have begun to investigate immunological responses to MSP1₁₉ in Atopi Parish in northern Uganda.

In this paper, we describe IgG subclass responses to MSP1₁₉ in Atopi residents. The majority of these subjects possessed cross-reactive IgG1 antibodies against all four sequence variants of MSP1₁₉. We also observed that MAD20 was the predominant allelic type of MSP1 present in Ugandan *P. falciparum* isolates.

MATERIALS AND METHODS

Study population and sample collection: Atopi Parish is located about 5 km west of Apac Town, 300 km north of Kampala. The population is predominantly of the Lango tribe and the major occupation is peasant agriculture. The description of the study population and preliminary malarimetric data has been reported elsewhere (Egwang *et al.*). During a cross-sectional survey carried out in December 1995, 1246 subjects were interviewed using a standard questionnaire and subjected to medical examination by a clinician. Blood samples from all subjects were collected in vacutainers containing EDTA. Thin and thick blood films were made for each sample, stained with Giemsa, and examined for malaria parasites under high power microscopy. Serum samples separated from blood were collected into fresh serum vials and transported on ice to Kampala where they were stored at -20 °C. Finger prick blood samples from children were collected onto filter papers (Whatman paper # 1); the filters were air dried, stored individually in plastic envelopes, and kept at 4°C until genomic DNA was extracted. The demographic and parasitologic data for 374 subjects whose serum and parasite isolates were used for the immunological and parasite genotyping studies are presented in Table 1.

Antigens, immunochemicals and primers: Four variants of MSP1₁₉, the carboxy terminal fragment of *Plasmodium falciparum* merozoite surface protein, namely Q-TSR, Q-KNG, E-TSR, and E-KNG produced in recombinant *Saccharomyces cerevisiae* were kindly provided by Dr David Kaslow (Molecular Vaccine Section, National Institute of Health, Bethesda, MD, USA). Alkaline phosphatase conjugated murine monoclonal antibodies to IgG1, IgG2, IgG3, and IgG4 antibodies were purchased from Zymed Laboratories, Inc, South San Francisco, CA, USA and from The Binding Site Limited, Birmingham, UK. Primers and protocols for genotyping *P. falciparum* isolates at the MSP1 locus by the polymerase chain reaction (PCR) were provided by Dr. Lisa Ranford Cartwright (Institute of Cell,

Animal, and Population Biology, University of Edinburgh, UK).

Enzyme-linked immunosorbent assays (ELISA): The E-KNG variant derived from the Palo Alto strain was chosen for initial studies and IgG subclass antibodies reacting with E-KNG were detected by ELISA. Immunolon 4 microtitre plates (Dynatech, UK) were coated overnight at 4°C with 1 µg/ml antigen in carbonate buffer. Plates were washed three times with phosphate buffered saline (PBS) containing 0.5 % v/v Tween 20 (PBS/T), blocked for one hour with 1% powdered skimmed milk in PBS/T (blocking buffer) and serum samples diluted 1:50 in blocking buffer were added to the plates in duplicate and incubated for one hour at 37°C. The plates were then washed three times in PBS/T and incubated for one hour at 37°C with alkaline phosphate conjugated mouse monoclonal antibodies against human IgG1, IgG2, IgG3, or IgG4 appropriately diluted in PBS/T. After the final wash, the reactions were developed by adding p-nitrophenyl phosphate (Sigma) and read at 405 nm after 30 minutes. Serum samples from 30 Europeans not previously exposed to malaria were employed as negative controls to obtain the cut-off value for positive antibody reactions. The cut-off value was calculated as the mean optical density (OD) plus two standard deviations of the European sera.

Competition ELISA: We identified two groups of serum samples: those which reacted strongly with all the variants, and those which reacted strongly with only E-KNG and Q-KNG variants when IgG1 antibodies were measured. Competition ELISA was therefore carried out in order to confirm the cross-reactivity of IgG1 antibodies against MSP1₁₉ sequence variants in the majority of serum samples. Plates were pre-coated with Q-KNG or E-KNG and blocked as described above. Selected serum samples in both categories were pre-incubated at room temperature with increasing quantities of Q-TSR in carbonate buffer for 5 hours and then added to the wells of the pre-coated microtitre plates. The plates were washed three times in PBS/T followed by incubation for one hour at 37°C with 100 µl of alkaline phosphate conjugated mouse monoclonal antibodies against human IgG1. All subsequent steps including development with the substrate were as described above for ordinary ELISA.

Parasite genotyping for MSP1 Block 17: *P. falciparum* DNA was extracted from filter papers, slides, or red blood cell pellets as described (15-17). We obtained *P. falciparum* isolates from other regions of Uganda either as slides (Kabarole) or as red blood cell pellets (Kampala). PCR primers used for amplifying

Table 1

Demographic and parasitological data for the subjects who provided sera for immunological studies of MSP1₁₉

Age (years)	N	Sex		<i>P. falciparum</i>	
		Male	Female	Prevalence (%)	Density (GM parasites/µl blood)
<1	4	3	1	100.0	60.0
1-5	39	18	21	92.3	1272.7
6-8	61	35	26	80.3	899.1
9-10	41	18	23	80.5	300.3
11-14	49	32	17	63.8	296.8
15-20	49	19	30	39.6	314.4
21-30	36	16	20	52.8	125.8
31-40	40	17	23	45.0	151.4
>40	53	29	24	51.9	137.8
Total	372	187	185	64.1	327.9

MSP1 block 17 included primers 1G (5'-AAS/GAT/ATY/TTA/AAT/TCA/CG-3') and 1H (5'-TT/ATT/TTC/GTT/ACA/AGT/AGG-3') for the first outer dimorphic PCR. Nested PCR using the outer PCR product as template was carried out using MAD20- and K1-specific forward primers designated 1A and 1B, respectively, as well as a common reverse primer 1C. The sequences of 1A, 1B, and 1C were 5'-GAG/AAG/TTC/CCA/TCA/TCA/CCA/C-3', 5'-GAA/TTG/CTG/ATT/TAT/CAA/CAG-3', and 5'-CAT/CTA/AAT/GTC/TGAIAC/ATC/C-3', respectively. Outer PCR was carried out using 1 µl of the *P. falciparum* DNA template in a 50-µl reaction volume containing 1.5 mM MgCl₂, 200 µM dNTP mix, 1.0 µg/µl primers, and 2.5 units of Taq polymerase (Promega) using the following conditions: pre-PCR incubation at 95°C for 5 min followed by incubation at 50°C for 5 min, followed by 39 cycles of 95°C for 1 min, 50°C for 45 sec, and 72°C for 1 min; during the last cycle, the extension at 72°C was for 10 minutes. Nested PCR was carried out using the inner primers 1A, 1B, and 1C at 1.0 µg/µl and outer PCR product as template. In this case, pre-PCR involved incubation of the samples at 94°C for 5 min followed by incubation at 54°C for 5 min; PCR consisted of 40 cycles, each cycle in turn consisting of 94°C for 1 min, 54°C for 1 min, and 72°C for 1 min; during the last cycle the extension at 72°C was again for 10 minutes. Ten µl of PCR products were run on a 2.5% agarose gel, stained with ethidium bromide, and photographed under UV transillumination.

Data analysis: Positive sera were those whose ODs were greater than the normal range (mean ± 2SD) for control European sera. Mean OD values were compared using the two sample Student's t test for equal variances. Proportions were compared by obtaining pooled proportions for unpaired samples. Possible associations between antibody response and age were tested using the chi-square test for trend analysis.

RESULTS

Increasing prevalence and concentration of antibodies to MSP1 19 with age: Three hundred and seventy four serum samples were tested in ELISA for IgG subclass reactivity with the E-KNG sequence variant of MSP1 19. The prevalence and the mean concentration of IgG1 and IgG3 antibodies generally increased with increasing age

(Figure 1, panels a and c; Table 2). Robust IgG1 responses seen in children 0-1 years old could be attributable to maternal antibodies; data from these children were excluded from the analyses. The prevalence of IgG1 antibodies in children 1-5 years old was lower than in subjects >14 years old (13.9 versus 61.4 %). This difference was statistically significant ($p < 0.001$). Mean OD values for IgG1 increased with age and, in general, individuals older than 14 years old had significantly elevated IgG1 levels. IgG3 antibodies, by contrast, had a delayed evolution, with robust responses beginning to appear only in children above seven to eight years old (Figure 1). Mean IgG3 levels remained low throughout the age groups and were significantly elevated only in individuals >40 years old (Table 2). Very few sera contained IgG2 or IgG4 antibodies to MSP1 19 and this did not change with age.

Figure 1

IgG subclass responses to MSP1 19 (E-KNG) as a function of age in a study population from Atopi Parish, Apac District in Northern Uganda. Panel (a), IgG1; panel (b), IgG2; panel (c), IgG3; and panel (d), IgG4. The age groups were defined as 1= 0-1 years, 2 = 1-2 years, 3 = 2-3 years, 4 = 3-4 years, 5 = 4-5 years, 6 = 5-6 years, 7 = 6-7 years, 8 = 7-8 years, 9 = 8-9 years, 10 = 10 years, 11 = 10-12 years, 12 = 12-14 years, 13 = 14-16 years, 14 = 16-20 years, 15 = 20-30 years, 16 = 30-40 years, 17 = >40 years.




Table 2

IgG1 and IgG3 subclass antibodies to MSP1 19 in sera of Atopi parish residents.^a

Age (years)	IgG1			IgG3		
	N	Mean OD (SD)	Prevalence (%)	N	Mean OD (SD)	Prevalence (%)
<1	4	1.107 (1.287)	50.0	5	0.308 (0.239)	40.0
1-5	36	0.352 (0.625)	13.9	39	0.183 (0.097)	38.5
6-8	54	0.375 (0.569)	22.2	55	0.230 (0.198)	45.5
9-10	29	0.439 (0.645)	33.3	36	0.304 (0.428)	55.6
11-14	42	0.612 (0.888)	31.1	41	0.361 (0.538)	53.7
15-20	44	1.024 (0.991) ^b	61.4 ^b	41	0.344 (0.299)	75.6 ^b
21-30	22	0.380 (0.464)	31.8	25	0.374 (0.284)	68.0 ^b
31-40	22	0.519 (0.711)	31.8	22	0.383 (0.505)	59.1
>40	22	1.511 (1.287) ^b	63.6 ^b	20	0.719 (0.834) ^b	85.0 ^b


^aValues are means with standard deviations SD in parenthesis and prevalence estimates of serum samples positive for antibodies.

^bSignificantly greater ($P < 0.05$) from the value for children in the age group 1-5 years.

Antibodies to MSP1₁₉ E-KNG cross-react with Q-TSR: In order to ascertain whether all the serum samples reacted equally strongly with other MSP1₁₉ variants; thirty six sera from adults with robust IgG1 responses against E-KNG were tested against all the sequence variants (E-KNG, E-TSR, Q-KNG and Q-TSR). None of these sera were able to discriminate between proteins carrying Q or E, i.e. OD values were closely correlated for Q-TSR versus E-TSR and values for Q-KNG were closely correlated with those for E-KNG (Figure 2a, 2b). However, three sera preferentially bound to KNG rather than TSR (Figure 2c, 2d). In several experiments, the three sera reacted with an OD < 0.5 against TSR variants while reacting with an OD ~ 2.0 against KNG variants.

Figure 2

OD values for IgG1 reactivity against different MSP1₁₉ sequence variants are correlated. Panel (a), Q-TSR versus E-TSR; panel (b), Q-KNG versus E-KNG; panel (c), Q-KNG versus Q-TSR; and panel (d), E-TSR versus E-KNG. Note the discordance between recognition of Q-KNG and Q-TSR in panel (c) for one serum sample (arrow head) and between recognition of E-KNG and E-TSR in panel (d) for two serum samples (arrow heads).



Cross reactivity of IgG1 antibodies to TSR and KNG was confirmed by competition ELISA (Figure 3). Sera were pre-incubated with soluble Q-TSR and then added to plates pre-coated with Q-KNG. Q-TSR inhibited binding to Q-KNG for two serum samples (795 and 606). These two sera, representative of the majority of serum samples, bound equally to Q-KNG and Q-TSR. By contrast, the binding of two other serum samples (997 and 395) to Q-KNG was unaffected by pre-incubation with Q-TSR; these sera reacted with Q-KNG but not to Q-TSR confirming the lack of cross-reactivity of IgG1 anti-Q-KNG with the Q-TSR variant.

Figure 3

Competition ELISA for IgG1 reactivity against Q-KNG after pre-incubation with various amounts of Q-TSR. There was competitive inhibition between Q-KNG and Q-TSR for samples 795 and 606, and lack of competitive inhibition for samples 997 and 395.




Table 3

Predominance of MAD20 over K1 alleles in *P. falciparum* isolates in Uganda.^a

Region ^b	N	MSP1 alleles		
		MAD20 (E-TSR)	K1 (Q-KNG)	Mixed (MAD20/K1)
Kampala (Central)	17	17 (17/17)	0 (0/17)	2 (2/17)
Kabarole (Western)	8	8 (8/8)	0 (0/8)	0 (0/8)
Apac (Northern)	8	8 (8/8)	0 (0/8)	1 (1/8)
Total	33	33 (33/33)	0 (0/8)	3 (3/33)
Percent		100	0	9

^aValues are numbers of samples containing the MSP1 allele with the frequency in parenthesis.

^bRegions from which the genotyped *P. falciparum* isolates were collected.

The predominant allele of MSP1₁₉ in Uganda is E-TSR (MAD 20): The presence of nested PCR products of approximately 480 and 230 bp representing MAD20 and K1 alleles, respectively, were scored in 33 individual *P. falciparum* isolates from three different regions of Uganda, namely, Central (Kampala), Western (Kabarole) and Northern (Apac) regions (Table 3). All isolates contained parasites of the E-TSR (MAD20) allelic type. However three isolates were mixed infections in which the E-TSR (MAD20) and Q-KNG (K1) allelic types were also detected, thus demonstrating the paucity of the K1 allelic type in these isolates.

DISCUSSION

MSP1₁₉ is a promising *P. falciparum* blood stage vaccine currently under development(1). Previous studies have shown that antibodies to the carboxy terminal fragment of MSP1 are associated with clinical immunity to malaria in West African children(13,14). The major IgG subclass response to MSP1₁₉ appears to be the opsonising IgG1 and

IgG3 antibodies which predominate in the sera of clinically immune individuals and which appear to be responsible for both inhibition of merozoite invasion of erythrocytes and killing of intra-erythrocytic parasites by monocytes (Egan, A.E *et al* in press). We have undertaken studies of human IgG subclass responses to *P. falciparum* MSP1₁₉ in a region of intense malaria transmission in Uganda with the major goal of studying the role of anti-MSP1₁₉ antibodies in clinical immunity to malaria and to attempt to extend the findings reported in West African children to children in this part of Uganda. Our studies have confirmed that IgG1 and IgG3 antibodies are the predominant IgG antibodies in residents of Atopi Parish and that the mean levels and prevalence of these antibodies increased with age. Interestingly, vigorous IgG1 responses appeared earlier and were evident in children as early as five years. Whereas in the Gambian study there was a distinct paucity of IgG3 antibodies, in the Ugandan study there was a significant and vigorous response (mean OD values and prevalence) by IgG3 subclass although strong IgG3 responses were delayed and appeared only in children above seven to eight years. As with the Gambian population, we observed almost background levels of the IgG2 and IgG4 subclass responses in Ugandan subjects. Our current data has one major limitation. The samples were obtained from one time point in a cross-sectional survey. Thus, although yielding important insights about the possible roles of IgG1 and IgG3 antibodies in the host-parasite relationship during malaria infection in our study population, the important correlations between antibody levels on the one hand, and parasite densities or clinical immunity on the other hand, can not be studied.

We confirmed that the majority of our study population have cross-reactive antibodies against all MSP1₁₉ variants. This is in agreement with previous studies in West Africa (18) and augurs well for the development of a vaccine based on MSP1₁₉. However, we have identified a small minority (8.3 %) of subjects who recognise only the KNG but not the TSR variants of MSP1₁₉. The impact of this finding to the future application of MSP1₁₉ vaccine remains unclear. Previous work has reported the predominance of MAD20 allelic types and a paucity of K1 allelic types in African *P. falciparum* isolates (19, 20). We have confirmed the abundance of MAD20 and the rarity of K1 allelic types in *P. falciparum* isolates from Atopi Parish and other areas of Uganda.

ACKNOWLEDGEMENTS

We are grateful to the District Medical Officer of Apac District for permission to carry out these studies and Mr. Victor Ochola for the mobilisation of the study subjects and for making the project possible. The co-operation of the Malaria Control Programme is also gratefully acknowledged. We would like to thank Dr. Albert Kilian for providing Giemsa-stained blood smears from Kabarole; Dr. Philippa Mudido Musoke for providing red blood cell pellets from malaria positive blood samples from Kampala; Dr. David Kaslow for the kind gift of recombinant MSP1₁₉ sequence variants; and Dr. Lisa Ranford-Cartwright for providing the primers and guidance with PCR genotyping. This study received financial support from the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), WHO, Geneva (Career Development Award Project 940849).

REFERENCES

- Howard, R.J. and Pasloske, B.L. Target antigens for asexual malaria vaccine development. *Parasitol. Today*. 1993; **9**:369-374.
- Chappel, J.A. and Holder, A.A. Monoclonal antibodies that inhibit *Plasmodium falciparum* invasion *in vitro* recognise the first growth factor-like domain of merozoite surface protein 1. *Mol. Biochem. Parasit.* 1993; **60**: 303-312.
- Diggs, C.L., Ballou, W.R. and Miller, L.H. The major surface protein as a malaria vaccine target. *Parasitol Today*. 1993; **9**: 300-302.
- Etlinger, H.M., Caspers, P., Matile, H., Schoenfeld, H.J., Stueber, D. and Takacs, B. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with *Plasmodium falciparum*. *Infect. Immun.* 1991; **59**: 3498- 3503.
- Siddiqui, W.A., Tam, L.Q., Kramer, K.J., Hui, G.S.N., Case, S.E. and Yamaga, K.M. *et al.* Merozoite surface coat precursor protein completely protects Aotus monkeys against *Plasmodium falciparum* malaria. *Proc. Natl Acad. Sci USA*. 1987; **84**: 3014-3018.
- Daly, T.M. and Long, C.A. A recombinant 15 kilodalton carboxy-terminal fragment of *Plasmodium yoelii* 17 XL merozoite surface protein 1 induces a protective immune response in mice. *Infect. Immun.* 1993; **61**: 2462-2467 .
- Doolan, D., Sedegah, M., Hedstrom, R.C., Hobart, P., Charoenvit, Y. and Hoffman, S.L. Circumventing genetic restriction of protection against malaria with multi-gene DNA immunisation: CD8+ T cell-, interferon -, and nitric oxide dependent immunity. *J Exp. Med.* 1996; **183**:1739-1746.
- Becker, S.I., Wang R., Hedstrom, R.C., Aguiar, J.C., Jones T.R., Hoffman S.L. and *et al.* Protection of mice against *Plasmodium yoelii* sporozoite challenge with *P.yoelii* merozoite surface protein 1 DNA vaccines. *Infect. Immun.* 1998; **66**: 3457-3461.
- Scherf, A., Mattei, D. and Sarthou, J L. Multiple infections and unusual distribution of block 2 of the MSA 1 gene of *Plasmodium falciparum* detected in West African clinical isolates by polymerase chain reaction analysis. *Mol. Biochem. Parasit.* 1991; **44**: 297-300.
- Miller, L.H., Robert, T., Shahabuddin, M. and McCutchan, T.F. Analysis of sequence diversity in the *Plasmodium falciparum* merozoite surface protein 1 (MSP-1). *Mol. Biochem. Parasitol.* 1993; **59**:1-14.
- Kaslow, D.C., Hui, G. and Kumar, S. Expression and antigenicity of *Plasmodium falciparum* major merozoite surface protein (MSP1₁₉) variants secreted from *Saccharomyces cerevisiae*. *Mol Biochem Parasitol.* 1994; **63**: 283- 289.
- Hui, G.S.N., Hashiro, C., Nikaido, C., Case, S.E., Hashimoto, A., Gibson. *et al.* Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of *Plasmodium falciparum* merozoite surface protein 1 expressed in Baculovirus. *Infect Immun.* 1993; **61**: 3403-341 1.
- Egan, A.F., Morris, J., Barnish, G., Allen, S., Greenwood, B.M., Kaslow, D.C. *et al.* Clinical immunity to *Plasmodium falciparum* is associated with serum antibodies to the 19 kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. *J. Infect. Dis.* 1996; **173**: 765-769.
- Riley, E.M, Allen, S.J., Willer, J.G., Blackman, M.J., Bennett S, Takacs B. *et al.* Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (pf MSP 1) of *Plasmodium falciparum* are associated with reduced malaria mortality. *Parasite immunol.* 1992; **14**: 321-337.
- Foley, M., Ranford-Cartwright, L.C. and Babiker, H.A. Rapid and simple method for isolating malaria DNA from fingerprick samples of blood. *Mol Biochem Parasitol.* 1992; **53**:241-244.
- Kain, K.C. and Lanar, D.E.L. Determination of genetic variation within *Plasmodium falciparum* by using enzymatically amplified DNA from filter paper disks impregnated with whole blood. *J. Clin. Microbiol.* 1991; **29**: 1171-1174.
- Kimura, M., Kaneko, O., Inoue, A., Ishii, A. and Tanabe, K. Amplification by polymerase chain reaction of *Plasmodium falciparum* DNA from Giemsa-stained thin blood smears. *Mol. Biochem. Parasit.* 1995; **70**: 193-197.
- Egan, A.E., Chappel, J.A., Burghaus, P.A., Morris, S.M., McBride, J.S., Holder, A.A. *et al.* Serum antibodies from malaria-exposed people recognise conserved epitopes formed by the two epidermal growth factor motifs of MSP1₁₉, the carboxy-terminal fragment of the major merozoite surface protein of *Plasmodium falciparum*. *Infect. Immun.* 1995; **63**: 456-466.
- Conway, D.J. Natural selection on polymorphic malaria antigens and the search for a vaccine. *Parasit. Today*. 1997; **13**: 26-29.
- Tanabe, K., Mackay, M., Goman, M. and Scaife, J.G. Allelic dimorphism in a surface antigen gene of the malaria parasite *Plasmodium falciparum*. *J. Mol Biol.* 1987; **195**: 273-287.